Mast Therapeutics Inc (NYSEMKT:MSTX) shares falls by 1.37%, Echo Therapeutics Inc (NASDAQ:ECTE)

Posted by Lynn Eisler May 29, 2013 0 Comment 647 views


Hartford, CT 05/29/2013 (GDPInsider) – Mast Therapeutics Inc (NYSEMKT:MSTX) shares closed at $0.720 per share, a fall of 1.37% (-$0.010) from its last closing price of $0.73. The stock had started this trading session at the opening price of $0.72 and has so far today seen a price ranging from a low of $0.66 to a high of $0.73. In its last 52-weeks’ history, the stock’s price has ranged from $0.45 – $0.92. While today 143.748 thousand shares have been traded so far, in the last 30 days, 202.420 thousand shares have been traded every day on an average. The company has an earnings-per-share of -$0.33 to show against 46.27 million outstanding shares, pointing towards losses and rough waters. The beta coefficient of 1.32 shows that the stock experiences 32% more volatility than the market and while that may potentially yield greater returns, it also tells the investor to be prepared for a steeper fall.

Is MSTX a solid investment at these levels? Get valuable updates and exclusive insights here.

Echo Therapeutics Inc (NASDAQ:ECTE) shares closed at $0.553 per share, a fall of 4.66% (-$0.027) from its last closing price of $0.58. The stock had started this trading session at the opening price of $0.61 and has so far today seen a price ranging from a low of $0.52 to a high of $0.61. In its last 52-weeks’ history, the stock’s price has ranged from $0.18 – $2.00. While today 236.604 thousand shares have been traded so far, in the last 30 days, 273.977 thousand shares have been traded every day on an average. The company has an earnings-per-share of -$0.31 to show against 60.24 million outstanding shares, pointing towards losses and rough waters. The beta coefficient of 0.49 shows that the stock experiences 51% less volatility than the market and while that may potentially yield smaller returns, it also tells the investor to not worry too much about a steeper fall.

How Should Investors Trade ECTE Now? Get key and important information right here.

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.


About Lynn Eisler

Lynn Eisler is a national news reporter focusing on economic issues, data analysis and the financial health of state and local governments. Lynn has been honored with the H.L. Mencken Award for Investigative Reporting, the Champion of Justice Award for reporting on the drug war, and the John Hancock Award for business reporting. Lynn was also a Knight Medical School Fellow at the University of Michigan.

View all post by Lynn Eisler Visit author's website

Write Your Comment